Product Description
BAT8013 is an antibody-drug conjugate (ADC) targeting CD25 developed by Bio-Thera Solutions, and is being developed for the treatment of advanced or metastatic solid tumors. By specifically binding to CD25 on the cell surface, BAT8013 enters the cell through receptor-mediated endocytosis. In the lysosomal environment, its linker is cleaved by cathepsins, releasing the cytotoxic payload Exatecan. As a topoisomerase I inhibitor, Exatecan causes the accumulation of single-strand DNA breaks, which are converted into double-strand breaks during replication, thereby triggering apoptosis. This mechanism selectively depletes regulatory T cells (Tregs) in the tumor microenvironment, improving the immunosuppressive tumor microenvironment, while also directly killing CD25⁺ tumor cells. (Sourced from: https://news.futunn.com/en/post/72939209/bio-thera-solutions-688177-sh-bat8013-for-injection-receives-clinical?level=1&data_ticket=1775055582982397)
Mechanisms of Action: CD25 Inhibitor, TOP1 Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Biothera
Company Location: Western America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|